Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for women with vestibulodynia: cream and pill combo under study

NCT ID NCT03844412

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two treatments for vestibulodynia, a chronic pain condition affecting the vulvar area. 209 women received either a lidocaine/estradiol cream, the antidepressant nortriptyline, both, or a placebo. The goal was to see which approach best reduces pain and improves daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine/estradiol cream and nortriptyline
What this could lead to
If successful, this could point toward more effective pain management options for women with vestibulodynia, improving their quality of life.
What could go wrong
This is a Phase 2 trial, so results are still early. The treatments may not work better than placebo, and side effects like skin irritation or drowsiness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

209 people

The number who actually took part.

Started

Nov 2019

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Female 2. Age 18-50 years 3. English-literate 4. Willingness to provide informed consent 5. Meeting criteria for diagnosis of VBD based on: 1. self-report of 3 continuous months of insertional (entryway) dyspareunia, and/or pain to touch/tampon insertion 2. pain score of ≥ 3 on the tampon insertion test Exclusion Criteria 1. Use of daily topical lidocaine, or estradiol, or lidocaine/estradiol to the vulvar vestibule within the past three months 2. Use of nortriptyline or other TCA medications within the past three months 3. Use of pregabalin or gabapentin within the past three months 4. Presence of active dermatologic vulvar disease or vaginal infection 5. Untreated atrophic vaginitis (participants may undergo treatment and re-evaluation for enrollment if the condition is resolved) 6. Previous vestibulectomy 7. Pregnant or planning on becoming pregnant during the study period. Within the first six months of the postpartum period. Currently breastfeeding/lactating, or within three months of discontinuing breastfeeding/lactation. 8. Active incarceration 9. Cancer within the past year. 10. Chemotherapy and/or radiation treatment within the past year. 11. Unstable medical condition (e.g., renal impairment, significant hematological disease, cardiovascular disease, hepatic insufficiency, neurological disorder, autoimmune disease, or respiratory illness) 12. Clear inflammatory states (e.g., morbid obesity) 13. Use of immunosuppressant medications 14. History of intolerance to nortriptyline, topical lidocaine, or topical estradiol 15. Contraindications to use of nortriptyline: current use, or use within the past 3 months, of MAOIs, SSRIs, SNRIs, NDRIs; recent (within the past year) myocardial infarction, active psychotic or suicidal thoughts, narrow angle closure glaucoma 16. Contraindications to the use of lidocaine or local anesthetics 17. Contraindications to the use of topical estrogen therapy 18. Post-menopausal, defined as no menses for 12 consecutive months or surgical removal of both ovaries. (Hysterectomy is not an exclusion) 19. Have not had Botox of the pelvic floor muscles in the last 12 months, or pelvic nerve blocks in the last three months. 20. Are not currently enrolled or planning to enroll in another clinical trial during the course of this trial. 21. Are not currently receiving pelvic physical therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Back pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27278, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.